Table 3.
Cell growth IC50 inhibitors in a panel of cell lines
| (A) Lymphoma cell lines | ||||||
|---|---|---|---|---|---|---|
| EZH2 status | WSU-FSCLL | WILL1 | DOHH2 | SC1 | DB | SUDLH8 |
| HKMT-I-005 | 3.405 | 5.599 | 3.257 | 3.711 | <1 | <1 |
| GSK343 | 2.868 | 17.91 | 6.151 | 12.12. | <1 | 5.11 |
| W.T. | W.T. | W.T. | W.T. | Mutant Y646N | W.T. | |
| (B) Breast cancer cell lines | ||||||
| IC50 (μM) | MDA-MB-231 | MCF-7 | T-47D | BT-474 | SkBr3 | MCF10a |
| HKMT-I-005 | 4.3 | 7.7 | 8.5 | 2.1 | 7.7 | >15 |
Cell growth IC50s (in μM) for a panel of cell lines, after treatment with HKMT-I-005 or GSK343: lymphoma cell lines (A), derived from cell counting following propidium iodide staining, and breast cancer cell lines (B), derived from MTT assays for cell viability. Mutation status of EZH2 is shown for each of the lymphoma cell lines